Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES

被引:48
|
作者
Nardese, V
Longhi, R
Polo, S
Sironi, F
Arcelloni, C
Paroni, R
DeSantis, C
Sarmientos, P
Rizzi, M
Bolognesi, M
Pavone, V
Lusso, P [1 ]
机构
[1] San Raffaele Sci Inst, DIBIT, Unit Human Virol, I-20132 Milan, Italy
[2] CNR, IRBM, I-20131 Milan, Italy
[3] San Raffaele Sci Inst, Lab Separat Tech, I-20132 Milan, Italy
[4] PRIMM Srl, I-20132 Milan, Italy
[5] Univ Eastern Piemonte, DISCAFF Dept, I-28100 Novara, Italy
[6] Univ Genoa, Adv Biotechnol Ctr, IST, I-16132 Genoa, Italy
[7] Univ Genoa, Dept Phys, INFM, I-16132 Genoa, Italy
[8] Univ Naples Federico II, Dept Chem, I-80126 Naples, Italy
[9] Univ Bologna, Dept Clin & Expt Med, I-40138 Bologna, Italy
关键词
D O I
10.1038/89653
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Certain chemokines act as natural antagonists of human immunodeficiency virus (HIV) by blocking key viral coreceptors, such as CCR5 and CXCR4, on the surface of susceptible cells. Elucidating the structural determinants of the receptor-binding and HIV-inhibitory functions of these chemokines is essential for the rational design of derivative molecules of therapeutic value. Here, we identify the structural determinants of CCR5 recognition and antiviral activity of the CC chemokine RANTES, showing that critical residues form a solvent-exposed hydrophobic patch on the surface of the molecule. Moreover, we demonstrate that the biological function is critically dependent on dimerization, resulting in the exposure of a large (similar to 180 Angstrom (2)), continuous hydrophobic surface. Relevant to the development of novel therapeutic approaches, we designed a retroinverted RANTES peptide mimetic that maintained both HIV- and chemotaxis-antagonistic functions.
引用
收藏
页码:611 / 615
页数:5
相关论文
共 50 条
  • [11] Choosing CCR5 or Rev siRNA in HIV-1
    H. Jose Arteaga
    Jorma Hinkula
    Iris van Dijk-Härd
    M. Sirac Dilber
    Britta Wahren
    Birger Christensson
    Abdalla J. Mohamed
    C. I. Edvard Smith
    [J]. Nature Biotechnology, 2003, 21 : 230 - 231
  • [12] HIV-1 infection and CCR5Δ32 homozygosis
    Ballana, Ester
    Este, Jose A.
    [J]. FUTURE VIROLOGY, 2012, 7 (07) : 653 - 658
  • [13] CCR5 as target for HIV-1 gene therapy
    Nazari, Reza
    Joshi, Sadhna
    [J]. CURRENT GENE THERAPY, 2008, 8 (04) : 264 - 272
  • [14] CCR5Δ32 Genotypes in a German HIV-1 Seroconverter Cohort and Report of HIV-1 Infection in a CCR5Δ32 Homozygous Individual
    Oh, Djin-Ye
    Jessen, Heiko
    Kuecherer, Claudia
    Neumann, Konrad
    Oh, Nari
    Poggensee, Gabriele
    Bartmeyer, Barbara
    Jessen, Arne
    Pruss, Axel
    Schumann, Ralf R.
    Hamouda, Osamah
    [J]. PLOS ONE, 2008, 3 (07):
  • [15] Global survey of genetic variation in CCR5, RANTES, and MIP-1α:: Impact on the epidemiology of the HIV-1 pandemic
    Gonzalez, E
    Dhanda, R
    Bamshad, M
    Mummidi, S
    Geevarghese, R
    Catano, G
    Anderson, SA
    Walter, EA
    Stephan, KT
    Hammer, MF
    Mangano, A
    Sen, L
    Clark, RA
    Ahuja, SS
    Dolan, MJ
    Ahuja, SK
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (09) : 5199 - 5204
  • [16] Gene polymorphisms in CCR5, CCR2, SDF1 and RANTES among Chinese Han population with HIV-1 infection
    Li, Hui
    Liu, Ting-Jun
    Hong, Ze-Hui
    [J]. INFECTION GENETICS AND EVOLUTION, 2014, 24 : 99 - 104
  • [17] Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy
    Mohamed, Hager
    Gurrola, Theodore
    Berman, Rachel
    Collins, Mackenzie
    Sariyer, Ilker K.
    Nonnemacher, Michael R.
    Wigdahl, Brian
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [18] Targeting CCR5 trafficking to inhibit HIV-1 infection
    Boncompain, Gaelle
    Herit, Floriane
    Tessier, Sarah
    Lescure, Aurianne
    Del Nery, Elaine
    Gestraud, Pierre
    Staropoli, Isabelle
    Fukata, Yuko
    Fukata, Masaki
    Brelot, Anne
    Niedergang, Florence
    Perez, Franck
    [J]. SCIENCE ADVANCES, 2019, 5 (10):
  • [19] CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro
    Salkowitz, JR
    Bruse, SE
    Meyerson, H
    Valdez, H
    Mosier, DE
    Harding, CV
    Zimmerman, PA
    Lederman, MM
    [J]. CLINICAL IMMUNOLOGY, 2003, 108 (03) : 234 - 240
  • [20] CCR5 genotype and resistance to vertical transmission of HIV-1
    Philpott, S
    Burger, H
    Charbonneau, T
    Grimson, R
    Vermund, SH
    Visosky, A
    Nachman, S
    Kovacs, A
    Tropper, P
    Frey, H
    Weiser, B
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (03): : 189 - 193